Australia Issues New Safety Warnings for GLP-1 Drugs Following Reports of Suicidal Thoughts
Key Insights
Australia's Therapeutic Goods Administration (search) issued safety alerts for GLP-1 (search) drugs including Ozempic and Mounjaro after reviewing 72 reports of suicidal ideation and 12 depression (search)-related incidents through September 2025.
The warning affects five approved GLP-1 (search) medications used by approximately 500,000 Australians for diabetes (search) management and weight control, though no proven causal link has been established.
A 2024 study found a 106% increase in suicidal behavior risk associated with GLP-1 (search) medicines, while conflicting research showed lower suicide risk in a study of 1.8 million patients.
Australia's Therapeutic Goods Administration (search) (TGA) has issued new safety warnings for GLP-1 (search) receptor agonist medications following reports of suicidal thoughts and mood changes among users. The November 30, 2025 safety alert affects five approved medications used by approximately 500,000 Australians: semaglutide (Ozempic, Wegovy), liraglutide (Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro).
Rising Safety Concerns Prompt Regulatory Action
The TGA's Advisory Committee on Medicines evaluated data showing 72 reports of suicidal ideation, 6 depression (search)-related suicides, 4 suicide attempts, and 2 completed suicides through September 2025. In the 12 months leading to November 2025, the Australian Database of Adverse Events Notifications recorded 20 cases of suicidal thoughts coinciding with GLP-1 (search) medicine use.
The warning follows similar actions by international regulatory bodies. The European Medicines Agency (search) (EMA), FDA, and World Health Organization identified semaglutide suicidal thought reports that exceeded those of other diabetes (search) medications in their adverse event databases.
Conflicting Research Evidence
Scientific studies present mixed findings on the mental health risks associated with GLP-1 (search) drugs. A 2024 study published in Scientific Reports found a 106% increase in the risk of suicidal behavior linked to GLP-1 medicines. An analysis of World Health Organization data also identified connections between semaglutide use and suicidal thoughts.
However, contradictory evidence emerged from a separate 2024 study analyzing data from more than 1.8 million patients taking the medicines for weight loss or diabetes (search). This research found a lower, not higher, risk of new or recurring suicidal thoughts compared with patients not taking GLP-1 (search) medicines.
JAMA research evaluating four semaglutide clinical trials demonstrated that psychiatric adverse events occurred at rates comparable to placebo in participants without pre-existing conditions.
Contraceptive Effectiveness Concerns
The TGA issued additional warnings about reduced oral contraceptive effectiveness, particularly with tirzepatide. Research first identified this potential interaction in 2003, with GLP-1 (search) medicines potentially affecting hormone absorption from oral contraceptives.
A review examining tirzepatide's interaction with oral contraception found this specific drug had a higher impact on hormone absorption compared with other GLP-1 (search) medications. While a 2015 study of semaglutide found no effect on hormone absorption for commonly used contraceptive pills, more recent 2025 research concluded that both tirzepatide and oral semaglutide could affect oral contraceptive hormone levels.
Clinical Recommendations and Patient Guidance
The TGA recommends patients taking GLP-1 (search) medicines immediately inform their doctors of new or worsening depression (search), suicidal thoughts, or unusual mood changes. For women taking tirzepatide with oral contraceptives, the agency advises switching to non-oral contraceptives or adding barrier methods for four weeks after starting treatment or increasing doses.
Dr. Terri-Lynne South from the Royal Australian College of General Practitioners explains that patients with depression (search), anxiety (search), or those taking antidepressants face higher risks of adverse effects. The TGA requires healthcare providers to assess patients' mental health backgrounds before initiating GLP-1 (search) receptor agonist treatment.
Understanding the Mechanism
GLP-1 (search) drugs work by imitating gut hormones to decrease hunger, delay stomach emptying, and enhance blood sugar management. Research indicates these medications affect dopamine reward systems in the brain, potentially producing mood changes. The Australian government distributed more than 2 million subsidized semaglutide prescriptions during 2023-24.
Common side effects including nausea and fatigue can create or intensify anxiety (search) symptoms in patients. The FDA analyzed 489 psychiatric adverse events in U.S. patients receiving semaglutide treatment, though the incidence of adverse effects remains low according to clinical trials.
Despite the warnings, the TGA maintains that no proven causal link exists between the medications and adverse mental health effects, while acknowledging the complex relationship between obesity (search), diabetes (search), and mental health. The agency demands additional studies while maintaining a cautious stance due to conflicting research results.